psoriasis: An autoimmune condition characterized by red, well-delineated plaques with silvery scales that are usually on the extensor surfaces and scalp. They can occasionally present with these manifestations: pustules; erythema and scaling in intertriginous areas, and erythroderma, that are often distributed on extensor surfaces and scalp.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
70 |
4. Check minimum number of eventsNone |
70 |
5. Include endpointsNone |
70 |
6. Filter based on genotype QC (FinnGen only) |
70 |
Control definitions (FinnGen only)
- Control exclude
- L12_PAPULOSQUAMOUS
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- L40
- Name in latin
- Acrodermatitis continua (Hallopeau)
Similar endpoints
↥List of similar endpoints to
Acrodermatitis continua
based on the number of shared cases.
Similar with more cases:
- Pustular psoriasis
- Psoriasis
- Papulosquamous disorders
- Autoimmune diseases related-to ILD
- Autoimmune diseases
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 449 | 266 | 181 |
| Only index persons | 419 | 250 | 169 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 55.60 | 54.91 | 56.85 |
| Only index persons | 55.27 | 54.78 | 55.99 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 70 | 45 | 25 |
| Unadjusted period prevalence (%) | 0.01 | 0.02 | 0.01 |
| Median age at first event (years) | 55.42 | 52.55 | 60.59 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
No data
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 65
- Matched controls
- 648
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
L40.2
ICD-10 Finland
Acrodermatitis continua
+∞
88.0
63
*
D05BB02
ATC
acitretin; oral
396.4
26.8
25
*
D07AD01
ATC
clobetasol; topical
23.4
26.6
44
53
D05AX52
ATC
calcipotriol, combinations; topical
40.5
25.5
32
15
L04AX03
ATC
methotrexate; systemic (immunosuppressants)
27.7
24.5
35
26
L40.0
ICD-10 Finland
Psoriasis vulgaris
173.8
23.3
23
*
M07.3*L40.5
ICD-10 Finland
Other psoriatic arthropathies
+∞
16.3
15
*
D07XC01
ATC
betamethasone, combinations; topical
14.0
15.8
29
35
E0000UV
ATC
NA
9.3
15.2
49
160
D05AX02
ATC
calcipotriol; topical
40.5
14.8
18
6
L40.5
ICD-10 Finland
Arthropathic psoriasis
95.6
14.2
15
*
319
Kela drug reimbursment
Adalimumab, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, sekukinumab and ustekinumab (skin psoriasis)
+∞
11.8
11
*
L30.9
ICD-10 Finland
Dermatitis, unspecified
7.5
10.8
29
63
E000001
ATC
NA
6.7
10.6
32
82
D07AC01
ATC
betamethasone; topical
5.8
10.2
40
140
L04AB04
ATC
adalimumab; parenteral
116.2
9.7
10
*
L40.8
ICD-10 Finland
Other psoriasis
+∞
9.6
9
*
S91
ICPC
Psoriasis
+∞
9.6
9
*
M07.3
ICD-10 Finland
Other psoriatic arthropathies
+∞
9.6
9
*
L40.3
ICD-10 Finland
Pustulosis palmaris et plantaris
43.3
9.3
11
*
D05AX03
ATC
calcitriol; topical
102.8
8.6
9
*
L40.9
ICD-10 Finland
Psoriasis, unspecified
38.7
8.3
10
*
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
11.8
8.3
15
16
E000003
ATC
NA
15.9
8.3
13
10
L30.3
ICD-10 Finland
Infective dermatitis
18.5
7.5
11
7
D07AC13
ATC
mometasone; topical
4.4
7.3
33
123
L01BA01
ATC
methotrexate; systemic (folic acid analog.)
10.5
6.9
13
15
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
6.4
6.5
17
34
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
8
6
14.80
5.21
1.3
1.0
—
—
—
0
0
9
17
5.90
3.64
1.8
2.1
—
—
—
0
0
19
79
2.93
3.51
2.2
1.8
—
—
—
0
0
9
18
5.57
3.50
1.8
2.3
—
—
—
0
0
5
6
8.84
2.79
1.4
1.2
—
—
—
0
0
58
456
2.59
2.38
14.0
7.4
78.0
75.5
u/l
0.31
58
429
31
197
2.03
2.14
4.5
3.0
—
—
—
0
0
8
26
3.34
2.08
1.8
1.7
—
—
—
0
0
5
11
4.80
1.97
1.2
1.5
—
—
—
0
0
42
313
1.85
1.69
7.3
6.2
12.1
10.8
umol/l
0.26
42
301
54
437
2.03
1.68
10.0
4.0
14.5
10.9
mm/h
1.32
54
402
0
39
0.00
1.39
0.0
1.5
—
—
—
0
0
14
78
1.99
1.33
3.3
3.2
1.1
0.9
e6/l
—
7
45
15
86
1.95
1.32
4.7
2.7
22.0
49.6
ng/l
—
10
61
5
19
2.75
1.23
2.0
2.5
—
—
—
0
0
5
19
2.75
1.23
1.8
1.6
—
340.7
—
0
10
37
284
1.64
1.20
5.1
3.7
0.0
0.0
estimate
—
8
53
8
41
2.07
1.13
2.1
1.4
—
—
—
0
0
19
125
1.71
1.09
3.9
2.2
—
—
—
0
0
18
117
1.72
1.07
1.4
1.7
0.8
1.0
mg/l
0.28
12
89
22
152
1.65
1.05
4.5
3.2
0.4
0.4
e6/l
0.02
17
116
36
282
1.57
1.03
6.1
5.6
1.2
1.2
mmol/l
0.02
27
242
31
235
1.57
1.02
2.7
2.3
82.0
77.8
nmol/l
0.33
26
212
10
56
1.92
0.93
2.4
1.4
—
—
—
0
0
10
57
1.88
0.89
2.5
1.6
—
—
—
0
0
64
592
1.94
0.80
25.4
12.7
18.5
22.2
mg/l
0.54
58
458
35
287
1.44
0.74
4.3
3.8
0.0
0.0
estimate
—
7
52
12
78
1.65
0.71
3.4
3.5
3.5
4.7
e6/l
—
5
45
19
142
1.46
0.63
2.0
3.0
2954.9
1079.1
ng/l
0.37
14
122
34
284
1.38
0.62
6.3
5.2
0.0
0.0
estimate
—
8
54
0
22
0.00
0.60
0.0
1.5
—
—
—
0
0
15
108
1.49
0.59
1.3
1.3
47.0
16.5
u/ml
—
6
44
25
204
1.35
0.50
3.4
3.4
16.7
33.3
ng/l
0.83
16
137
5
33
1.55
0.42
1.8
2.7
2.2
6.4
ug/l
—
5
28
0
16
0.00
0.41
0.0
1.6
—
—
—
0
0
5
34
1.51
0.41
2.2
4.0
0.2
0.1
e6/l
—
5
34
8
113
0.67
0.41
1.5
1.4
—
—
—
0
0
0
19
0.00
0.39
0.0
1.4
—
—
—
0
0
0
19
0.00
0.39
0.0
1.4
—
—
—
0
0
0
19
0.00
0.39
0.0
1.4
—
—
—
0
0
57
542
1.28
0.27
20.3
12.5
89.3
83.9
ml/min/173m2
1.36
51
438
30
270
1.19
0.25
5.0
3.8
—
—
—
0
0
5
40
1.27
0.23
3.2
2.5
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
2.8
—
—
—
0
0
0
14
0.00
0.20
0.0
1.0
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
0
14
0.00
0.20
0.0
2.1
—
0.2
—
0
7
0
14
0.00
0.20
0.0
1.0
—
—
—
0
0
40
374
1.16
0.19
3.3
3.0
—
—
—
0
0
7
61
1.16
0.18
1.1
3.5
—
—
—
0
0
8
67
1.22
0.17
16.5
7.8
—
—
—
0
0
52
539
0.86
0.15
5.1
4.8
38.6
39.1
mmol/mol
0.17
47
509
13
113
1.18
0.14
3.8
5.3
17.5
21.1
%
—
6
55
12
105
1.17
0.12
1.8
1.4
—
—
—
0
0
10
86
1.19
0.11
2.9
2.9
2.5
2.5
mmol/l
—
10
75
17
157
1.11
0.08
2.5
1.6
1.3
1.2
mmol/l
0.20
12
138
58
592
0.88
0.08
20.3
13.8
139.3
139.8
mmol/l
0.80
58
578
8
76
1.06
0.08
2.1
2.0
—
—
—
0
0
13
141
0.90
0.06
1.3
1.4
19.9
22.8
nmol/l
0.35
13
122
55
560
0.92
0.05
4.4
4.1
6.0
5.8
mmol/l
0.98
50
523
56
569
0.92
0.04
5.7
4.2
4.5
4.7
mmol/l
1.13
50
532
24
231
1.06
0.03
4.3
3.6
—
—
—
0
0
57
578
0.93
0.03
4.6
4.6
2.7
2.8
mmol/l
0.42
52
535
21
213
0.98
0.00
2.1
1.8
88.3
99.6
pmol/l
0.43
13
104
59
591
0.99
0.00
20.2
13.9
3.9
4.0
mmol/l
1.41
59
577
16
156
1.03
0.00
4.8
3.8
0.0
0.0
estimate
—
7
51
15
146
1.03
0.00
4.9
5.4
2.2
1.8
ug/l
0.19
15
126
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0
6
62
0.96
0.00
3.7
2.7
25.5
32.8
u/l
—
6
53
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
3.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
0.00
0.0
2.2
—
14.2
—
0
6
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
3.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
0.3
—
0
5
0
5
0.00
0.00
0.0
1.2
—
89.0
—
0
5
7
70
1.00
0.00
2.0
1.8
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint L12_PSORI_ACRODERM and mortality.
Females
No dataMales
No dataMortality risk
Mortality risk for people of age
years, who have L12_PSORI_ACRODERM.| N-year risk | Females | Males |
|---|---|---|
| 1 | No data | No data |
| 5 | No data | No data |
| 10 | No data | No data |
| 15 | No data | No data |
| 20 | No data | No data |
Relationships between endpoints
↥Index endpoint: L12_PSORI_ACRODERM – Acrodermatitis continua
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data